JP2013545734A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545734A5 JP2013545734A5 JP2013536812A JP2013536812A JP2013545734A5 JP 2013545734 A5 JP2013545734 A5 JP 2013545734A5 JP 2013536812 A JP2013536812 A JP 2013536812A JP 2013536812 A JP2013536812 A JP 2013536812A JP 2013545734 A5 JP2013545734 A5 JP 2013545734A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- nos
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40712810P | 2010-10-27 | 2010-10-27 | |
| US61/407,128 | 2010-10-27 | ||
| PCT/US2011/058025 WO2012058393A2 (en) | 2010-10-27 | 2011-10-27 | Dkk1 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016175266A Division JP6353500B2 (ja) | 2010-10-27 | 2016-09-08 | Ｄｋｋ１抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545734A JP2013545734A (ja) | 2013-12-26 |
| JP2013545734A5 true JP2013545734A5 (https=) | 2014-08-21 |
| JP6066912B2 JP6066912B2 (ja) | 2017-01-25 |
Family
ID=44910313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536812A Active JP6066912B2 (ja) | 2010-10-27 | 2011-10-27 | Ｄｋｋ１抗体およびその使用方法 |
| JP2016175266A Active JP6353500B2 (ja) | 2010-10-27 | 2016-09-08 | Ｄｋｋ１抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016175266A Active JP6353500B2 (ja) | 2010-10-27 | 2016-09-08 | Ｄｋｋ１抗体およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9879072B2 (https=) |
| EP (3) | EP3219725B1 (https=) |
| JP (2) | JP6066912B2 (https=) |
| AR (2) | AR083740A1 (https=) |
| AU (3) | AU2011319843C1 (https=) |
| CA (2) | CA2815181C (https=) |
| ES (1) | ES2863626T3 (https=) |
| MX (3) | MX354481B (https=) |
| TW (2) | TWI636994B (https=) |
| WO (1) | WO2012058393A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE481487T1 (de) | 1998-11-27 | 2010-10-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
| US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
| US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
| US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
| CA2815181C (en) * | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
| EA201391248A1 (ru) | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
| AP3981A (en) | 2011-03-25 | 2017-01-05 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
| SI2739311T1 (en) | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
| EP3712168A3 (en) | 2011-12-28 | 2020-10-14 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| US9708388B2 (en) * | 2012-04-11 | 2017-07-18 | Hoffmann-La Roche Inc. | Antibody light chains |
| AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
| AU2013334790A1 (en) | 2012-10-23 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using Wnt pathway-binding agents |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| WO2017127706A1 (en) * | 2016-01-22 | 2017-07-27 | Yale University | Compositions and methods for inhibiting dkk-1 |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| EP3692061A1 (en) | 2017-10-04 | 2020-08-12 | Amgen Inc. | Transthyretin immunoglobulin fusions |
| EP4169576A1 (en) * | 2018-03-23 | 2023-04-26 | University of Massachusetts | Gene therapeutics for treating bone disorders |
| EP3774879B1 (en) | 2018-03-30 | 2026-01-28 | Amgen Inc. | C-terminal antibody variants |
| US20210079079A1 (en) * | 2018-05-02 | 2021-03-18 | Ortheus, Inc. | Systems and methods for local modulation of wnt signaling |
| SG11202108398YA (en) * | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| PH12021551720A1 (en) | 2019-03-01 | 2022-03-28 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
| CN112180094A (zh) * | 2019-07-04 | 2021-01-05 | 上海东慈生物科技有限公司 | Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用 |
| TR201920272A1 (tr) * | 2019-12-15 | 2021-06-21 | Uludamar Altay | Dental i̇mplantlar, greft materyalleri̇ ve prf i̇le osseoi̇ntegrasyonun artirilmasi i̇çi̇n bi̇r terapöti̇k kompozi̇syon ve bunun lokal kullanim yöntemleri̇ |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| WO2023143444A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
| WO2024253462A1 (ko) * | 2023-06-07 | 2024-12-12 | 중앙대학교 산학협력단 | 스클레로스틴 억제제를 유효성분으로 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
| CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6344541B1 (en) | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| EP2319301B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human Ig lambda light chain genes |
| WO2006015373A2 (en) * | 2004-08-04 | 2006-02-09 | Amgen Inc | Antibodies to dkk-1 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| AR060017A1 (es) * | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| CA2677356A1 (en) * | 2007-02-08 | 2008-08-14 | Zhiqiang An | Antibodies specific for dkk-1 |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP2012502649A (ja) * | 2008-09-19 | 2012-02-02 | メディミューン，エルエルシー | Ｃｄ１０５を対象とする標的結合剤およびその使用 |
| NZ596274A (en) | 2009-05-12 | 2013-11-29 | Pfizer | Blocking anti-dkk-1 antibodies and their uses |
| CA2815181C (en) * | 2010-10-27 | 2020-09-15 | William Gleason Richards | Dkk1 antibodies and methods of use |
| EA201391248A1 (ru) * | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
| SI2739311T1 (en) * | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
| EP3712168A3 (en) * | 2011-12-28 | 2020-10-14 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2011
- 2011-10-27 CA CA2815181A patent/CA2815181C/en active Active
- 2011-10-27 US US13/878,619 patent/US9879072B2/en active Active
- 2011-10-27 EP EP17169408.6A patent/EP3219725B1/en active Active
- 2011-10-27 CA CA3085710A patent/CA3085710A1/en active Pending
- 2011-10-27 MX MX2013004726A patent/MX354481B/es active IP Right Grant
- 2011-10-27 TW TW105125647A patent/TWI636994B/zh active
- 2011-10-27 WO PCT/US2011/058025 patent/WO2012058393A2/en not_active Ceased
- 2011-10-27 AU AU2011319843A patent/AU2011319843C1/en active Active
- 2011-10-27 EP EP11779531.0A patent/EP2632951B1/en active Active
- 2011-10-27 JP JP2013536812A patent/JP6066912B2/ja active Active
- 2011-10-27 AR ARP110103984A patent/AR083740A1/es active IP Right Grant
- 2011-10-27 EP EP20213270.0A patent/EP3838922A1/en active Pending
- 2011-10-27 TW TW100139221A patent/TWI636993B/zh active
- 2011-10-27 ES ES17169408T patent/ES2863626T3/es active Active
- 2011-10-27 MX MX2017013617A patent/MX382826B/es unknown
-
2013
- 2013-04-26 MX MX2021001494A patent/MX2021001494A/es unknown
-
2016
- 2016-06-03 AU AU2016203722A patent/AU2016203722A1/en not_active Abandoned
- 2016-09-08 JP JP2016175266A patent/JP6353500B2/ja active Active
-
2017
- 2017-12-13 US US15/841,065 patent/US10800839B2/en active Active
-
2018
- 2018-02-23 AU AU2018201333A patent/AU2018201333B2/en active Active
-
2020
- 2020-02-10 AR ARP200100356A patent/AR118047A2/es unknown
- 2020-09-09 US US17/015,212 patent/US12297260B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545734A5 (https=) | ||
| JP2018193386A5 (https=) | ||
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| NZ597466A (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
| HRP20171190T1 (hr) | Protutijelo protiv beta-amiloida i njegove upotrebe | |
| HRP20171978T1 (hr) | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitijela dobivenih hucal gold tehnologijom, specifičnih za humani cd38 | |
| RU2017132160A (ru) | Антитела к pd-l1 и их применение для усиления функции t-клеток | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| JP2012523417A5 (https=) | ||
| RU2019125027A (ru) | Афукозилированные антитела к рецептору фактора роста фибробластов fgfr2iiib | |
| NZ606584A (en) | Binding proteins for hepcidin | |
| NZ610091A (en) | Antibodies | |
| RU2534564C3 (ru) | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| JP2011526785A5 (https=) | ||
| JP2016502515A5 (https=) | ||
| JP2015508763A5 (https=) | ||
| JP2017534259A5 (https=) | ||
| JP2018512124A5 (https=) |